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Genetic diagnosis of patients with neurodevelopmental disorders is imperative and
a standard clinical practice. Considering the continuous accumulation of data on
disease-causing variants, reanalysis of previously established sequencing data is
important. Periodic reanalysis of variants with uncertain significance has become
mandatory in clinical laboratories. Therefore, to confirm the utility of the reanalysis of
targeted gene panel data in clinical laboratories, we re-evaluated the data of two groups
of patients who had undergone targeted gene panel testing for neurodevelopmental
disorders (n = 116) and epileptic encephalopathy (n = 384). This reanalysis was
based on a reannotation process reflecting updated databases. Six (5.2%) and seven
(1.8%) new pathogenic or likely pathogenic variants were identified in these two groups,
respectively, attributable to the updated guidelines and de novo reports from unrelated
patients. Although relatively low, considerable increase in the diagnostic yield was
confirmed. We suggest that reanalysis of genetic variants, mainly using changes in
databases and updated interpretations, should be implemented as a routine practice
in clinical laboratories.
Keywords: reanalysis, next-generation sequencing, epileptic encephalopathy, neurodevelopmental disorder,
clinical laboratories
INTRODUCTION
Adoption of massive parallel sequencing has revolutionized the molecular genetic diagnosis
of patients with genetically heterogeneous neurodevelopmental disorders. Advancements in
technology and development of cost-effective methods have improved the feasibility of multigene
panel testing with hundreds of relevant genes and whole-exome sequencing in clinical laboratories.
An average diagnostic yield of up to 40% is reported depending on patient group and intensity of
analysis (1–5).
Given the continuous accumulation of data on the relationship between gene–disease and
variant–disease, periodic reanalysis of the already reported patient results has been considered
(6). Several studies have reported that reanalysis using improved bioinformatic tools and updated
databases or expanded knowledge on genotype–phenotype correlation is beneficial for the
diagnosis of previously unsolved cases (6–14). Furthermore, periodic reanalysis of variants with
uncertain significance has now become mandatory in clinical laboratories (15).
The increased diagnostic yield of reanalysis is mostly attributed to newly established
gene–disease relationships following initial exome sequencing (16). However, in clinical
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laboratories that perform the majority of genetic testing using
specific gene panels rather than larger whole-exome or whole-
genome sequencing, the identification of new pathogenic or likely
pathogenic variants based on newly discovered gene–disease
relationships is limited. It is also difficult to change bioinformatic
tools in clinical laboratories; reanalysis is inevitable, and mainly
based on updated databases related to variants or updated
guidelines. While next-generation sequencing (NGS) guidelines
recommend reanalysis of previously negative NGS data (17),
performing reanalysis is difficult in clinical laboratories owing to
limited resources. Moreover, the utility of the reanalysis process
has been questioned because it is labor-intensive.
Herein, we re-evaluated the established results of targeted
gene panel testing in patients with neurodevelopmental
disorders, including those with delayed development, intellectual
disability, and epileptic encephalopathy, to confirm the




Gene panel sequencing data were collected from patients who
had undergone gene panel testing for neurodevelopmental
disorders (n = 116) and epileptic encephalopathy (n = 384)
between January 2017 and July 2018. No pathogenic or likely
pathogenic variants were identified. In our clinical laboratory,
gene panel testing for epileptic encephalopathy was performed
when the patients showed specific epilepsy syndromes, probably
related to developmental, and epileptic encephalopathy.
Further, gene panel testing for neurodevelopment disorders was
performed when the patients presented seizures, not specifically
epilepsy syndrome or severe developmental delays. The xGen
Inherited Diseases Panel (Integrated DNA Technologies,
Coralville, IA, USA) comprising 4,503 genes was used for
neurodevelopmental disorders, and a customized gene panel
comprising 173 candidate genes (Supplementary Table 1) was
used for epileptic encephalopathy. This study was approved by
the institutional review board of Severance Hospital, and the
requirement for informed consent was waived-off.
Data Analysis and Interpretation
We used a comprehensive custom bioinformatic pipeline that
supported a wide range of variants, ranging from single-
nucleotide variants to copy-number variants. The flow chart
of our bioinformatic pipeline was as previously described
(18, 19) without any modification. We only re-annotated the
variant call format (VCF) files of patients with no pathogenic
or likely pathogenic variants for reanalysis (Figure 1). All
annotation processes were automatically performed. The variants
from VCF files were first annotated using Annovar and
Variant Effect Predictor software to determine their effects on
genes, transcripts, protein sequences, and regulatory regions.
The variants were then annotated using ClinVar, Online
Mendelian Inheritance in Man (OMIM), the Human Gene
MutationDatabase (HGMD), computational (in silico) predictive
FIGURE 1 | Visual representation of the reanalysis workflow. VCF, variant call
format; VEF, Ensembl Variant Effect Predictor; HGMD, Human Gene Mutation
Database; OMIM, Online Mendelian Inheritance in Man.
programs (Mutation Taster, SIFT, PolyPhen-2, PROVEAN),
Single Nucleotide Polymorphism Database (dbSNP), 1000
Genome, the Exome Aggregation Consortium, the Genome
Aggregation Database, and the Korean Reference Genome
Database. These databases were updated four times per year in
our laboratory. Following automated annotation, benign or likely
benign variants were filtered out by tallying the scores from the
frequency of variant-expressing population, in silico results, and
the literature reported in the databases. We manually checked
the automatically re-annotated data and performed parental tests
when possible. Reanalysis was performed fromMay to July 2019.
The pathogenicity of variants was classified according to the
American College of Medical Genetics and Genomics and the
Association for Molecular Pathology (ACMG/AMP) guidelines
(17). We used the ClinGen recommendation for de novo
criteria as indicated in the Sequence Variant Interpretation (SVI)
Working Group (https://clinicalgenome.org/working-groups/
sequence-variant-interpretation/). This recommendation for de
novo criteria suggests a point-based system to determine the
strength of de novo evidence (ACMG/AMP criteria codes PS2
and PM6) based on confirmed vs. assumed status, phenotypic
consistency, and number of de novo observations. We also
used the recommendations by the SVI working group for
interpretation of the PVS1 criterion for exon duplication (20).
RESULTS
Overall Increase in Diagnostic Yield
In total, 66 of 116 (56.9%) patients who were tested using
the neurodevelopmental disorder panel and 231 of 384 (60.2%)
patients tested by the gene panel for epilepsy were male. Six
pathogenic or likely pathogenic variants were identified in the
patients subjected to gene panel testing for neurodevelopmental
disorders, accounting for an increase of 5.2% (6/116) in the
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diagnostic yield. Of the 384 patients previously subjected to
gene panel testing for epilepsy, seven new pathogenic or
likely pathogenic variants were identified during the course
of reanalysis; this accounted for an increase of 1.8% (7/384)
in the diagnostic yield. During the initial testing, parental
testing had not been conducted for 13 patients owing to
the omission or rejection of consent, but it was triggered by
changed classification of the variants during reanalysis; we could
perform parental testing on three patients (P1, P8, and P13).
Except for P11, parents of other 12 patients had shown no
symptoms similar to their children. The upgraded variants are
described in Table 1. The variants of uncertain significance
reported in the initial report for the 13 cases are presented in
Supplementary Table 2.
Updated Guidelines, New Variant–Disease
Associations, and Phenotyping
The SVI Working Group suggested in 2018 that the discovery of
a de novo variant in unrelated patients might allow its prediction
in patients with unaffected parents. The variants from P1-P7,
P9-P10, and P12-P13 with unaffected parents were de novo in
unrelated patients in the new literature. Therefore, they were
given various levels of pathogenic evidence by the sum of points
(Table 1). We contacted their parents to explain the results
of reanalysis and received consent for parental testing from
the parents of P1 and P13. The variants from P1 and P13
were confirmed to be de novo. In addition, the variants from
P3 and P13 were associated with the PS3 code, owing to the
new literature on decreased protein function. The P3 variant
in ITPR1, a gene encoding a calcium channel that modulates
intracellular calcium signaling, was shown to decrease calcium
ion release in the endoplasmic reticulum (21). The P13 variant
in KCNC1, encoding a highly conserved subunit of a potassium
ion channel, was demonstrated to decrease the amplitude of
current (22). In the case of ALDH7A1 (P8), which is associated
with the recessive disease pyridoxine-dependent epilepsy, two
variants were identified near the intronic junction; these were
not canonical splice variants but were reported as variants
of uncertain significance owing to the lack of evidence. The
variant c.192+3A>T (NM_001182.4) was thought to be likely
pathogenic in ClinVar in October 2017 after our initial report
and was assigned the PP5 code. After additional phenotyping that
identified decreased seizures with pyridoxine administration, the
variant was assigned the PP4 code and deemed to be likely
pathogenic. Considering the reinterpretation of c.192+3A>T
variant to be likely pathogenic, the variant c.1093+5G>T was
likely to receive PM3 score owing to its trans position with
the variant c.192+3A>T. The patient’s parents were informed
of the reanalysis results and the need for a parent test. The
variant c.1093+5G>T in ALDH7A1 was actually identified
in trans with c.192+3A>T following parental testing. Exon
duplication, unlike exon deletion, has not been described in detail
in the ACMG/AMP guidelines published in 2015; thus, exon
3,4 duplication in GRIN2A in P11 was reported as a variant
of uncertain significance (Supplementary Figure 1). However,
in 2018, new guidelines for PVS1 were released (20), and
the code PVS1_Strong was assigned for the exon duplication
in GRIN2A because the reading frame was thought to be
disrupted and the occurrence of non-sense-mediated decay
was predicted.
Changed Genetic Inheritance or Updated
Gene–Disease Associations
As P6 was a female patient, one missense variant in ALG13,
known to be inherited in an X-linked recessive mode, was
underestimated in our initial report. However, the mode
of inheritance in ALG13 changed from X-linked recessive
to X-linked dominant. Therefore, the likelihood of disease
association of the variant c.320A>G (NM_001099922.2) in
ALG13 increased in P6. It was deemed to be likely pathogenic,
as it was reported as de novo in other patients. The initial
diagnostic test was performed, and CACNA1E encoding a
subunit of a calcium channel was considered a candidate
for epileptic encephalopathy; however, the OMIM database
did not clearly report this gene and the related disease.
Therefore, we conservatively interpreted the CACNA1Emissense
variant as a variant of uncertain significance (P7). CACNA1E
was linked to epileptic encephalopathy in OMIM in 2019
(CACNA1E, OMIM# 601013); thus, the CACNA1E variant
c.1054G>A (NM_001205293.1) in P7 became more noticeable
and was interpreted as a likely pathogenic de novo variant from
unrelated patients.
DISCUSSION
Neurodevelopmental disorders, including epileptic
encephalopathy, affect more than 3% children worldwide (23).
The genetic diagnosis of these diseases is gaining importance,
and NGS technology with massive parallel sequencing has
become the standard clinical practice. Approximately 250 novel
gene–disease and 9,200 novel variant–disease associations are
reported every year (6). Therefore, the significance of reanalysis
of negative results obtained from previous rounds of NGS cannot
be overemphasized.
Several reports have described the reanalysis of whole-exome
or clinical-exome sequencing data, showing varying yields from
approximately 10% to 30% performed by applying improved
bioinformatic pipelines or searching for newly discovered
disease-associated genes (6–14). To achieve maximum diagnostic
yield, realignment with upgraded tools through the inspection
and clarification of patients’ symptoms and signs, data sharing
and collaboration with other institutes, and reannotation
of variants using updated databases should be periodically
performed. However, the process of reanalysis in clinical
laboratories is limited because it is time consuming and labor-
intensive. Furthermore, frequent changes in analytical pipelines
may hinder routine work, and patients can only be contacted
when they visit centers for appointment. In addition, detailed
phenotyping is often difficult, given the limited treatment
time available.
In the present study, we performed reanalysis of the
previous data using updated guidelines, new variant–disease



































TABLE 1 | Characteristics of the newly identified pathogenic or likely pathogenic variants according to the ACMG/AMP guidelines.
ID Gender Gene
panel
































































































































ND, neurodevelopment; AD, autosomal dominant; AR, autosomal recessive; XLD, X-linked dominant; PVS, pathogenic very strong; PS, pathogenic strong; PM, pathogenic moderate; PP, pathogenic supporting.
*Codes written in bold imply new evidence after reanalysis.
The numbers in parentheses mean total points awarded according to ClinGen Sequence Variant Interpretation Recommendation for de novo Criteria. The phenotypic consistency in P1 and P4-P13 with epilepsy was considered
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associations with some phenotyping, new genetic inheritance,
and updated gene–disease associations, all of which contributed
to the increase in the diagnostic yield. We reanalyzed the
results using two gene panels comprising 173 and 4,503
genes based on limited conditions. For efficient bioinformatic
analysis, we incepted with VCF files and used automated
annotation programs (Figure 1). This process allowed us to
reduce labor and time because it excluded the need to
manually search the databases. We identified six new pathogenic
or likely pathogenic variants (5.2%) in 116 patients who
underwent neurodevelopmental disorder panel testing and
seven new pathogenic or likely pathogenic variants (1.8%) in
384 patients who underwent epileptic encephalopathy panel
testing. The increase in the diagnostic yield was relatively
low, possibly due to the lack of updates with respect to
newly established gene–disease associations. It may also be
attributed to the fact that we performed panel sequencing,
not exome sequencing, without changing the previously used
bioinformatic tools and without in-depth phenotyping. Although
the cost reduction for large-scale genome sequencing may
increase the utilization of whole-exome sequencing as a routine
practice, many clinical laboratories still employ gene panels
with a limited number of target genes (24). The identification
of 13 new pathogenic or likely pathogenic variants using
targeted gene panel results demonstrates the benefit of this
approach, considering the limited time and resources available in
clinical laboratories.
We learnt several lessons from the reanalysis of targeted
panel sequencing data at the clinical laboratory level. First,
it is important to keep a track of the relevant guidelines
for the correct interpretation of variants. The ACMG/AMP
guidelines published in 2015 provide information on variant
interpretation necessary during the initial testing but may
lack some explanation. The updated recommendation
for de novo criteria highlighted that de novo reports
from unrelated patients could help interpret the variants.
In addition, the updated guidelines for the PVS1 code
provided us with the evidence for the interpretation of
exon duplication.
Second, even during reanalysis, identifying variants related
to the cause of an underlying disease may be useful to treat
patients. In the case of P8, ALDH7A1 variants associated with
pyridoxine-dependent epilepsy were thought to be related to
patient’s seizures, and the administration of pyridoxine improved
seizures in this patient. In the case of P4, clonazepam that
was found to be effective in patients with the same GLRA1
variant related to hyperekplexia (25) could be administered to
our patient.
Third, it is advantageous to include as many relevant
genes as possible during the designing of gene panel. During
reanalysis, the yield of our gene panel for neurodevelopment
disorders with a higher number of genes was higher
than that of the gene panel for epileptic encephalopathy.
ZDHHC9, ITPR1, and GLRA1 showed meaningful variants
in the gene panel for neurodevelopment disorders during
reanalysis but were not actually included in the gene panel for
epileptic encephalopathy.
Our study has a few limitations. The reanalysis was performed
on two different set of panels, not by exome sequencing, owing
to the nature of the clinical laboratory. Hence, it was difficult to
reveal the variants upgraded from the discovery of new gene–
disease associations. In addition, only unsolved cases were subject
to reanalysis. Future studies should be conducted on previously
pathogenic or likely pathogenic variants.
In conclusion, we reanalyzed the data obtained using a
small and large gene panel, starting with VCF files. The main
factors were updated guidelines and de novo reports from
other patients. Although relatively low, the increase in the
diagnostic yield was considerable. This approach may encourage
the implementation of data reanalysis as a routine process in
clinical laboratories.
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